How plausible may be a conference on IP (and regulatory) exclusivity? Sufficiently By Gabriele Girardello on Monday, November 14, 2022 #economics #UPC biotech and pharmaceutical conference clinical trial data data and market exclusivity Gabriele Girardello patent exclusivity regulatory data second medical indication SPC +
Conference report: Innovation and Competition in Life Sciences Law - Part I By Mark Schweizer on Monday, June 12, 2017 conference report EU competition law European patent law regulatory data reverse payment settlements +
Shall we dance? Regulatory approval, trade secrets and the transatlantic biosimilars patent wars By Annsley Merelle Ward on Sunday, March 12, 2017 AmeriKat biologics biosimilars BPCIA EFPIA fujifilm marketing authorisation patent litigation patent strategy regulatory approval regulatory data trade secrets us patent litigation +
Does the economic impact of SPCs necessitate SPC Regulation reform? The European Commission wants to find out By Annsley Merelle Ward on Thursday, January 19, 2017 AmeriKat data and market exclusivity data protection economics of pharmaceutical IP EU Commission marketing authorisation regulatory data SPC tender SPCs +
AIPPI Congress Report 3: Biosimilars - into the great unknown? By Annsley Merelle Ward on Wednesday, September 17, 2014 AIPPI AIPPI Congress AmeriKat biosimilars counterfeits event report pharmaceutical industry regulatory data Toronto +
More to read ... By Jeremy on Sunday, January 28, 2007 .eu domain names artist's resale right droit de suite Jeremy Phillips regulatory data +